The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Abstract
CD73 generation of immunosuppressive adenosine within the hypoxic tumor microenvironment causes dysregulation of immune cell infiltrates, resulting in tumor progression, metastases, and poor disease outcomes. Therapies targeted toward the adenosinergic pathway, such as antibodies targeting CD73 and CD39, have proven efficacy in mouse tumor models; however, humanized versions are only in preliminary development. In contrast, A2A adenosine receptor antagonists have progressed to late-stage clinical trials in Parkinson disease, yet evidence of their role in oncology is limited. This review will compare the merits and challenges of these therapeutic approaches, identifying tumor indications and combinations that may be fruitful as they progress to the clinic. Significance: High concentrations of immunosuppressive adenosine have been reported in cancers, and adenosine is implicated in the growth of tumors. This brief review delineates the current treatment strategies and tumor subtypes that will benefit from targeting adenosinergic pathways, alone or in combination with contemporary approaches to cancer treatment. Cancer Discov; 4(8); 879–88. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
A2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N. A., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15337 · Cited by 679
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215337 · Cited by 660
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
Stagg, J., Divisekera, U., McLaughlin, N., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908801107 · Cited by 572
Self-citationExtracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 571
Self-citationEnjyoji, K., Sévigny, J., Lin, Y., Frenette, P. S., Christie, P. D., Esch, J. S. A., Imai, M., Edelberg, J. M., Rayburn, H., Lech, M., et al. (1999) · Nature Medicine · doi:10.1038/12447 · Cited by 565
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540 · cited 1×
“Release of tumor-derived exosomes expressing catalytically functional CD39 and CD73 represents an additional mechanism of tumor-mediated immunosuppressive adenosine generation (17).”
BackgroundCD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Loi, S., Pommey, S., Haibe-Kains, B., Beavis, P. A., Darcy, P. K., Smyth, M. J., & Stagg, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222251110 · Cited by 492
Self-citationTargeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Allard, B., Pommey, S., Smyth, M. J., & Stagg, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0545 · Cited by 458
Self-citation(1997) · PubMed · Cited by 433
Adenosine receptors in regulation of dendritic cell differentiation and function
Novitskiy, S. V., Ryzhov, S., Zaynagetdinov, R., Goldstein, A. E., Huang, Y., Tikhomirov, O. Y., Blackburn, M. R., Biaggioni, I., Carbone, D. P., Feoktistov, I., et al. (2008) · Blood · doi:10.1182/blood-2008-02-136325 · Cited by 430 · cited 1×
“Adenosine polarizes myeloid cells to develop into immunosuppressive phenotypes such as M2 macrophages and tolerogenic dendritic cells (DC) due to A2A and A2B adenosine receptor signaling, respectively (18).”
BackgroundCD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
Stagg, J., Divisekera, U., Duret, H., Sparwasser, T., Teng, M. W. L., Darcy, P. K., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4246 · Cited by 401
Self-citationOhta, A., Kini, R., Ohta, A., Subramanian, M., Madasu, M., & Sitkovsky, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00190 · Cited by 398
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 345
Self-citationHIF‐dependent induction of adenosine A2B receptor in hypoxia
Kong, T., Westerman, K. A., Faigle, M., Eltzschig, H. K., & Colgan, S. P. (2006) · The FASEB Journal · doi:10.1096/fj.06-6419com · Cited by 335
Sun, X., Wu, Y., Gao, W., Enjyoji, K., Csizmadia, E., Müller, C. E., Murakami, T., & Robson, S. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.007 · Cited by 279
Chemotherapy induces ATP release from tumor cells
Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J.-L., Zitvogel, L., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.22.10026 · Cited by 278
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice
Wang, L., Fan, J., Thompson, L. F., Zhang, Y., Shin, T., Curiel, T. J., & Zhang, B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45559 · Cited by 262
Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells
Ryzhov, S., Novitskiy, S. V., Goldstein, A. E., Biktasova, A., Blackburn, M. R., Biaggioni, I., Dikov, M. M., & Feoktistov, I. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101225 · Cited by 261
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
Sim, G. C., Martin-Orozco, N., Jin, L., Yang, Y., Wu, S., Washington, E., Sanders, D., Lacey, C., Wang, Y., Vence, L., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci46266 · Cited by 229
Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors
Cekic, C., Sag, D., Li, Y., Theodorescu, D., Strieter, R. M., & Linden, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101845 · Cited by 201
Desmet, C. J., Gallenne, T., Prieur, A., Reyal, F., Visser, N. L., Wittner, B. S., Smit, M. A., Geiger, T. R., Laoukili, J., Iskit, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222085110 · Cited by 172
Anti‐CD73 therapy impairs tumor angiogenesis
Allard, B., Turcotte, M., Spring, K., Pommey, S., Royal, I., & Stagg, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.28456 · Cited by 171
Self-citationAiras, L., Niemelä, J., Salmi, M., Puurunen, T., Smith, D. J., & Jalkanen, S. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.136.2.421 · Cited by 163
Vaqué, J. P., Dorsam, R. T., Feng, X., Iglesias-Bartolome, R., Forsthoefel, D. J., Chen, Q., Debant, A., Seeger, M. A., Ksander, B. R., Teramoto, H., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.018 · Cited by 162
Altered purinergic signaling in CD73‐deficient mice inhibits tumor progression
Yegutkin, G. G., Marttila‐Ichihara, F., Karikoski, M., Niemelä, J., Laurila, J. P., Elima, K., Jalkanen, S., & Salmi, M. (2011) · European Journal of Immunology · doi:10.1002/eji.201041292 · Cited by 156
Host A2B Adenosine Receptors Promote Carcinoma Growth
Ryzhov, S. V., Novitskiy, S. V., Carbone, D. P., Biaggioni, I., Zaynagetdinov, R., Goldstein, A. E., Dikov, M. M., & Feoktistov, I. (2008) · Neoplasia · doi:10.1593/neo.08478 · Cited by 151
Airas, L. M., Hellman, J., Salmi, M., Bono, P., Puurunen, T., Smith, D. J., & Jalkanen, S. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.5.1603 · Cited by 147
Lin, J.-N., Lin, V. C.-H., Rau, K., Shieh, P., Kuo, D., Shieh, J., Chen, W. J., Tsai, S., & Way, T. (2009) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf9035782 · Cited by 143
Serra, S., Horenstein, A. L., Vaisitti, T., Brusa, D., Rossi, D., Laurenti, L., D'Arena, G. F., Coscia, M., Tripodo, C., Inghirami, G., et al. (2011) · Blood · doi:10.1182/blood-2011-08-374728 · Cited by 142
Terp, M. G., Olesen, K. A., Arnspang, E. C., Lund, R. R., Lagerholm, B. C., Ditzel, H. J., & Leth‐Larsen, R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301274 · Cited by 141
Fishman, P. (1992) · International Journal of Oncology · doi:10.3892/ijo_00000008 · Cited by 132
Leth‐Larsen, R., Lund, R. R., Hansen, H. V., Lænkholm, A., Tarin, D., Jensen, O. N., & Ditzel, H. J. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800061-mcp200 · Cited by 129
AMP Is an Adenosine A1 Receptor Agonist
Rittiner, J. E., Korboukh, I., Hull-Ryde, E. A., Jin, J. J., Janzen, W. P., Frye, S. V., & Zylka, M. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.291666 · Cited by 127
Disordered Purinergic Signaling Inhibits Pathological Angiogenesis in Cd39/Entpd1-Null Mice
Jackson, S. W., Hoshi, T., Wu, Y., Sun, X., Enjyoji, K., Cszimadia, E., Sundberg, C., & Robson, S. C. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070190 · Cited by 113
Häusler, S. F., del Barrio, I. M., Diessner, J., Stein, R. G., Strohschein, J., Hönig, A., Dietl, J., & Wischhusen, J. (2014) · Europe PMC (PubMed Central) · Cited by 109
Deletion of Cd39/Entpd1 Results in Hepatic Insulin Resistance
Enjyoji, K., Kotani, K., Thukral, C., Blumel, B., Sun, X., Wu, Y., Imai, M., Friedman, D. J., Csizmadia, E., Bleibel, W., et al. (2008) · Diabetes · doi:10.2337/db07-1265 · Cited by 105
Mediavilla-Varela, M., Luddy, K. A., Noyes, D. R., Khalil, F. K., Neuger, A. M., Soliman, H. H., & Antonia, S. J. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.25643 · Cited by 102
A2B adenosine receptor blockade inhibits growth of prostate cancer cells
Wei, Q., Costanzi, S., Balasubramanian, R., Gao, Z., & Jacobson, K. A. (2013) · Purinergic Signalling · doi:10.1007/s11302-012-9350-3 · Cited by 100
CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study
Stemmer, S. M., Benjaminov, O., Medalia, G., Ciuraru, N. B., Silverman, M. H., Bar‐Yehuda, S., Fishman, S., Harpaz, Z., Farbstein, M., Cohen, S., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0211 · Cited by 93
Sun, X., Han, L., Seth, P., Shu, B., Li, L., Csizmadia, E., JUNGER, W. G., Schmelzle, M., Usheva, A., Tapper, E. B., et al. (2012) · Hepatology · doi:10.1002/hep.25989 · Cited by 90
Ntantie, E., Gonyo, P., Lorimer, E., Hauser, A. D., Schuld, N. J., McAllister, D. M., Kalyanaraman, B., Dwinell, M. B., Auchampach, J. A., & Williams, C. L. (2013) · Science Signaling · doi:10.1126/scisignal.2003374 · Cited by 90
Airas, L. M., Niemelä, J., & Jalkanen, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5411 · Cited by 84
Ecto-5′-nucleotidase (CD73) promotes tumor angiogenesis
Wang, L., Tang, S., Wang, Y., Xu, S., Yu, J., Zhi, X., Ou, Z., Yang, J., Zhou, P., & Shao, Z. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9571-z · Cited by 75
Tóth, I., Le, A. Q., Hartjen, P., Thomssen, A., Matzat, V., Lehmann, C., Scheurich, C., Beisel, C., Busch, P., Degen, O., et al. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0113018 · Cited by 66
The effects of scleroderma serum on human microvascular endothelial cells
Marks, R. M., Czerniecki, M., Andrews, B. S., & Penny, R. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780311209 · Cited by 55
NT5E CpG island methylation is a favourable breast cancer biomarker
Nigro, C. L., Monteverde, M., Lee, S., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.212 · Cited by 41
Cited by
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Pitt, J. M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,338
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
Self-citationSun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Self-citation
Metadata
- Authors
- Young, A., Mittal, D., Stagg, J., & Smyth, M. J.
- Venue
- Cancer Discovery
- Published
- 2014-08-01
- Volume
- 4
- Issue
- 8
- Pages
- 879-888
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2144174481
- Cited by
- 310
- References
- 57
- FWCI
- 17.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.